CollPlant Reports Successful Bio-Printing Of 200cc Breast Implants And Additional Pre-Clinical Data
Portfolio Pulse from Benzinga Newsdesk
CollPlant has successfully bio-printed 200cc breast implants and reported positive pre-clinical data showing tissue growth and no adverse reactions. Large-animal studies are ongoing with results expected in Q4 2024 and Q1 2025.

June 06, 2024 | 11:16 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
CollPlant's successful bio-printing of 200cc breast implants and positive pre-clinical data are significant milestones. The ongoing large-animal studies and expected results in Q4 2024 and Q1 2025 could drive future commercial demand and impact stock prices.
The successful bio-printing of 200cc breast implants and positive pre-clinical data indicate significant progress in CollPlant's technology. The absence of adverse tissue reactions and ongoing large-animal studies suggest potential for future commercial demand, which could positively impact stock prices.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100